LifeArc Ventures
VC Fund
London, United Kingdom
LifeArc Ventures is a VC fund in London focused on Health Care and Biotechnology. LifeArc Ventures a self-funding medical research charity that invests in Seed and Series-A stage Biotech and Healthtech companies.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries LifeArc Ventures invests in
Stages LifeArc Ventures invests in
Countries LifeArc Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 4 (22%)
- Biotechnology 4 (22%)
- Therapeutics 3 (17%)
- Life Science 2 (11%)
- Pharmaceutical 2 (11%)
Stage
- Series A 4 (22%)
- Series B 3 (17%)
- Seed 2 (11%)
- Funding Round 1 (6%)
Country
- United Kingdom 4 (22%)
- United States 2 (11%)
- Sweden 1 (6%)
- Germany 1 (6%)
- Switzerland 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Imran Hamid
Senior Investment Principal
|
Senior Investment Principal | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M / Series A / Jun 24, 2026 | ||
| Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | ||
| exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | ||
| Affect Therapeutics is using mobile technology to revolutionize stimulant addiction recovery. | $26M / Series B / Sep 23, 2025 | ||
| GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M / Series B / May 27, 2025 | ||
| Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. | $24.7M / Series A / Mar 26, 2025 | ||
| Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases. | $67M / Series A / Mar 25, 2025 | ||
| Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M / Series A / Mar 17, 2025 | ||
| Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M / Series A / Dec 16, 2024 | ||
Ikarovec
|
Ikarovec is developing novel gene therapies to treat major ophthalmic indications. | $10.3M / Seed / Oct 23, 2024 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does LifeArc Ventures invest in?
LifeArc Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact LifeArc Ventures?
Public channels for LifeArc Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LifeArc Ventures?
The team at LifeArc Ventures includes Imran Hamid (Senior Investment Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
